Novo Nordisk rises after Wegovy data

Shares in Novo Nordisk NOVOb.CO rise around 3% after the Danish drugmaker said its weight-loss drug Wegovy cuts heart risk by 57% versus rival treatments from Eli Lilly LLY.N

Nordnet analyst Per Hansen points to the study as a reason for the share price move, though notes that question is how important the data is to investors

"In reality, investors have not attached greater importance to these positive effects," Hansen says, adding that the weight loss has been the most important factor in terms of investment

Novo's domestic peer Zealand Pharma ZELA.CO is up around 4% in early trade

Up to previous session close, Novo stock was down around 43% YTD